Alexion Pharmaceuticals (NASDAQ:ALXN) CFO Vikas Sinha sold 50,000 shares of the company’s stock on the open market in a transaction dated Monday, October 28th. The stock was sold at an average price of $122.97, for a total transaction of $6,148,500.00. Following the sale, the chief financial officer now directly owns 310,808 shares in the company, valued at approximately $38,220,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.14% on Wednesday, hitting $125.50. 1,290,101 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52-week low of $81.82 and a 52-week high of $126.39. The stock has a 50-day moving average of $113.8 and a 200-day moving average of $104.. The company has a market cap of $24.556 billion and a P/E ratio of 70.18.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, October 24th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
ALXN has been the subject of a number of recent research reports. Analysts at Oppenheimer raised their price target on shares of Alexion Pharmaceuticals from $115.00 to $125.00 in a research note to investors on Friday, October 25th. Separately, analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals from $97.00 to $106.00 in a research note to investors on Friday, October 25th. They now have a “hold” rating on the stock. Finally, analysts at Guggenheim raised their price target on shares of Alexion Pharmaceuticals from $127.00 to $130.00 in a research note to investors on Friday, October 25th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $121.72.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.